Evidence map›Paper›PMID 33879618›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

DDX11 loss causes replication stress and pharmacologically exploitable DNA repair defects.

Nanda Kumar Jegadesan, Dana Branzei

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Nanda Kumar JegadesanThe FIRC Institute of Molecular Oncology, Italian Foundation for Cancer Research, 20139, Milan, Italy.ORCID 0000-0002-2710-0656
Dana BranzeiThe FIRC Institute of Molecular Oncology, Italian Foundation for Cancer Research, 20139, Milan, Italy; dana.branzei@ifom.eu.ORCID 0000-0002-0544-4888
IFOM · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

DNA RepairDrug Resistance, NeoplasmMolecular Targeted TherapyAntineoplastic AgentsCisplatinDEAD-box RNA HelicasesDNA HelicasesGenes, BRCA1Genes, BRCA2HeLa CellsHumansPoly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsCisplatinDDX11 protein, humanDEAD-box RNA HelicasesDNA HelicasesPoly(ADP-ribose) Polymerase InhibitorsBRCA1/2chemotherapyDDX11homologous recombinationreplication stress

Identifiers

PMID33879618
PMCPMC8092582
OpenAlexW3152704929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.